The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2025 | What is considered an “optimal” response when treating a patient with myeloma with CAR-T?
In this video, Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses what could be considered an “optimal” response to CAR T-cell therapy in patients with multiple myeloma (MM). Dr Hansen notes that the ideal outcome is a measurable residual disease (MRD)-negative complete remission (CR). However, she states that a partial response (PR) or better is also desirable, particularly in later lines of treatment. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Certainly when treating patients with CAR-T, it depends on whether patients are being treated in earlier line or patients being treated in later line. The best response would be a complete remission or better and MRD negative status or state. That would be ideal. Not necessarily going to be the case for all patients, particularly as you treat patients later in the disease course who are heavily pretreated, have a large disease burden that we are trying to debulk with bridging therapies...
Certainly when treating patients with CAR-T, it depends on whether patients are being treated in earlier line or patients being treated in later line. The best response would be a complete remission or better and MRD negative status or state. That would be ideal. Not necessarily going to be the case for all patients, particularly as you treat patients later in the disease course who are heavily pretreated, have a large disease burden that we are trying to debulk with bridging therapies. But I think as long as we get at least a partial response or better, particularly in late line, that’s desirable, but ideally a complete response MRD negative would be the ideal situation for any of our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
